CAV1 and neoplasm: Using heterogeneous PDX models with varying levels of CAV1, we show that TDM1, an ADC that targets HER2, combined with lovastatin, a small molecule that depletes cholesterol in ways that modulate CAV1 protein expression, improves antibody-tumor binding and response rates better than either does alone.